Research: Avoid Piperacillin-tazobactam When Treating BSI Caused by Ceftriaxone-resistant Pathogens

28th ECCMID: The MERINO Trial: piperacillin-tazobactam versus meropenem for the definitive treatment of bloodstream infections caused by third-generation cephalosporin nonsusceptible Escherichia coli or Klebsiella spp.: an international multi-centre openlabel non-inferiority randomised controlled trial (free abstract)

Commentaries: Avoid piperacillin-tazobactam when treating BSI cause by ceftriaxone-resistant pathogens – European Society of Clinical Microbiology and Infectious Diseases, via EurekAlert (free) AND Combo antibiotic found inferior for MDR bloodstream infections – CIDRAP (free)